Once retatrutide becomes commercially available, transitioning from semaglutide would be a clinical decision made with your provider
It is a real drug with real constraints, not a stick-on sticker
The psychological impact of quick body changes sometimes exacerbates underlying mental health conditions
Weeks 9 to 16: Progressive Dose Escalation (1.0mg to 1.7mg) By the time most patients reach the 1.0mg dose, they have generally developed a good understanding of their personal side effect triggers and have adopted dietary strategies that minimise discomfort
Patients should report persistent stool changes to their GP, particularly if accompanied by abdominal pain, as GLP-1 therapy carries rare risks of pancreatitis and gallbladder disease
however, the extent to which smooth muscle cells contribute to the antiatherosclerotic properties of GLP-1 remains to be determined